Product Information
Registration Status: ActiveSIN15206P
TRAVATAN C EYE DROP SOLUTION 30MCG/ML is approved to be sold in Singapore with effective from 2017-04-10. It is marketed by NOVARTIS (SINGAPORE) PTE LTD, with the registration number of SIN15206P.
This product contains Travoprost 0.03mg/ml in the form of SOLUTION, STERILE. It is approved for OPHTHALMIC use.
This product is manufactured by S.A. Alcon-Couvreur N.V. in UNITED STATES, andAlcon Laboratories Inc - ASPEX in BELGIUM.
It is a Prescription Only Medicine that can only be obtained from a doctor or a dentist, or a pharmacist with a prescription from a Singapore-registered doctor or dentist.
Product Reference
Important Note: For generic product, the SPC/PIL provided may not be brand specific.
{{/items}} {{^items}}Description
Travoprost ophthalmic solution is a topical medication used for controlling the progression of glaucoma or ocular hypertension, by reducing intraocular pressure. It is a synthetic prostaglandin F2alpha analogue.
Indication
Ophthalmic solution used for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension who are intolerant of other intraocular pressure lowering medications or insufficiently responsive (failed to achieve target IOP determined after multiple measurements over time) to another intraocular pressure lowering medication.
Mechanism of Action
Travoprost free acid is a selective FP prostanoid receptor agonist and is believed to reduce intraocular pressure by increasing the drainage of aqueous humor, which is done primarily through increased uveoscleral outflow and to a lesser extent, trabecular outflow facility.
Pharmacokinetics
- Absorption
- Systemically absorbed when administered to the eye.
- Distribution
- Metabolism
- Travoprost, an isopropyl ester prodrug, is hydrolyzed by esterases in the cornea to its biologically active free acid. Systemically, travoprost free acid is metabolized to inactive metabolites via beta-oxidation of the α(carboxylic acid) chain to give the 1,2-dinor and 1,2,3,4-tetranor analogs, via oxidation of the 15-hydroxyl moiety, as well as via reduction of the 13,14 double bond.
- Elimination
Toxicity
Symptoms of overexposure include irritation to the skin, eyes, nose, throat, and respiratory tract.
Active Ingredient/Synonyms
Isopropyl (Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-{(1e,3R)-3-hydroxy-4-[(alpha,alpha,alpha-trifluoro-m-tolyl)oxy]-1-butenyl}cyclopentyl)-5-heptenoate | Travoprost | Travoprostum | Travoprost |
Source of information: Drugbank (External Link). Last updated on: 3rd July 18. *Trade Name used in the content below may not be the same as the HSA-registered product.